whats up break out you say!, page-2

Eiffel signed a couple of feasibility study deals with a major pharmaceutical company in November last year and February of this year. Results from both these studies should be available by now - and success in either would be enough to underpin a major lift in EIF's current price.

The February release pointed to the significance of a successful study, noting "It’s a pity that commercial constraints prevent us from naming the company involved " and "This latest project is particularly exciting for us because the drug we are working with is a drug that is currently on the market. If the feasibility study is successful, the time to market will be relatively short and hence any licensing revenue which may accrue to Eiffel may be accelerated."

If the studies have delivered good results I guess the major pharmaceutical company will be ready to cough up some serious dollars to get access to the technology. My view is that the renewed interest in EIF is because an announcement is imminent on the success of the studies and on who the major pharmaceutical company is. Expect a significant re-rating of this forgotten bio-tech to happen very quickly if this proves to be the case.